Samsung Epis Holdings Launches Epis NexLab to Pioneer Next-Generation Biotech Platforms and Drive Global Innovation
Samsung Epis Holdings Co., Ltd. has officially announced the establishment of Epis NexLab Co., Ltd., a wholly owned subsidiary dedicated to advancing next-generation biotechnology platforms. The formation of this new entity marks a significant milestone in Samsung Epis Holdings’ long-term strategy to expand its presence beyond biosimilars and into cutting-edge therapeutic discovery and platform innovation.
Epis NexLab will serve as a center of excellence for pioneering biotechnology research, focusing on the transformation of highly scalable core technologies into powerful, adaptable platforms that enable the discovery of new drug candidates. These technologies will be leveraged not only to drive in-house research but also to support collaborative partnerships and licensing opportunities with leading global pharmaceutical companies.
The new subsidiary’s primary objective is to accelerate the development of innovative drug modalities, including amino acid and peptide conjugate platform technologies, to unlock new treatment possibilities across multiple therapeutic areas. This initiative aligns with Samsung’s broader mission to establish a global leadership position in the next wave of biotechnology innovation.
Strategic Vision and Leadership
At the helm of Epis NexLab is Peter Seongwon Hong, who will serve as Chief Executive Officer (CEO). Hong will continue in his concurrent roles as Executive Vice President and Head of Research and Early Development at Samsung Bioepis, bringing extensive expertise in biologics development and translational research to guide the new company’s strategic direction. In addition, he will hold a position as a non-executive director on the board of Samsung Epis Holdings, ensuring cohesive alignment between the parent company and its newest subsidiary.
Commenting on the launch, Hong expressed his enthusiasm about the company’s potential to redefine the future of biotech innovation.
Building on the R&D expertise accumulated through years of developing quality-assured biologics at Samsung Bioepis, we will focus on securing next-generation biotechnology platforms that can drive sustainable growth for the new company beyond the biosimilar business,” said Peter Seongwon Hong, CEO of Epis NexLab. “Our long-term goal is to become a leading biotechnology company in next-generation therapeutic technologies, and we will be relentless in our efforts to drive this growth through innovative research, advanced platform development, and strategic investment.”
A New Chapter in Samsung’s Biotech Evolution
The establishment of Epis NexLab represents a strategic evolution in Samsung Epis Holdings’ biotechnology portfolio. Since its inception, Samsung Bioepis has been recognized for its success in biosimilar development, achieving global market penetration and regulatory milestones across multiple regions. With Epis NexLab, the company now aims to broaden its scope beyond biosimilars to novel therapeutic modalities, positioning itself at the forefront of next-generation biologics and platform technologies.
Through Epis NexLab, Samsung Epis Holdings intends to explore and develop platform-based discovery models that enable the identification and optimization of novel drug candidates at scale. By focusing on modular and adaptable biotechnological frameworks—particularly those involving peptide and amino acid conjugates—the subsidiary aims to establish highly efficient discovery pipelines that can generate multiple therapeutic candidates across diverse indications.
This platform-based approach is designed to reduce development timelines, enhance scalability, and increase the probability of clinical success, offering a distinct competitive advantage in the evolving global biotech landscape.
Driving Innovation Through Collaboration
A core pillar of Epis NexLab’s strategy will be its commitment to collaboration and open innovation. The company plans to engage in joint development partnerships and license-out agreements with leading global pharmaceutical and biotech organizations. By fostering these alliances, Epis NexLab seeks to amplify its research capabilities, expand its scientific network, and accelerate the translation of innovative concepts into viable therapies.
In addition, the new subsidiary will explore cross-disciplinary synergies, integrating insights from computational biology, artificial intelligence, and molecular engineering to optimize the discovery process. Epis NexLab’s advanced R&D infrastructure will enable the seamless transition from platform research to preclinical and early-stage development, positioning the company as a valuable innovation partner for the global pharmaceutical ecosystem.
A Commitment to Scientific Excellence and Sustainable Growth
Epis NexLab’s foundation is deeply rooted in the scientific rigor and operational excellence that have defined Samsung Bioepis’ success in the biosimilar market. The new subsidiary will continue this legacy, emphasizing research quality, reproducibility, and compliance with global standards.
By focusing on next-generation therapeutic technologies, Epis NexLab aims to contribute to sustainable healthcare innovation. Its mission extends beyond product development—toward building an integrated platform ecosystem that supports ongoing discovery, innovation, and commercialization across multiple therapeutic domains.
The company’s R&D efforts will target emerging and complex disease areas, where traditional therapeutic approaches face limitations. Through the application of advanced peptide-based and conjugate technologies, Epis NexLab aspires to unlock new mechanisms of action and expand treatment possibilities for patients worldwide.
Founding and Corporate Structure
Formed in 2025, Epis NexLab is a 100% wholly owned subsidiary of Samsung Epis Holdings, reflecting the parent company’s full commitment to advancing innovation in biotechnology. The establishment of the subsidiary underscores Samsung’s strategic intent to diversify its biotech portfolio and invest in the future of advanced therapeutics.
The company’s operational framework will integrate cutting-edge research capabilities, state-of-the-art laboratory facilities, and a multidisciplinary scientific team to ensure agile and high-quality innovation. Epis NexLab’s governance structure, guided by experienced leadership and cross-functional collaboration, is designed to support both scientific discovery and long-term business growth.
A Vision for the Future of Biotech
As the biotechnology sector undergoes rapid transformation driven by scientific advances and technological convergence, Epis NexLab is positioning itself as a future-oriented innovator. Its strategic roadmap includes:
- Developing proprietary next-generation platform technologies that can serve as foundations for multiple therapeutic programs.
- Expanding collaborative networks to include global pharmaceutical partners, academic institutions, and research organizations.
- Leveraging AI-driven analytics and computational tools to enhance drug discovery precision and efficiency.
- Pursuing targeted investments in emerging therapeutic areas with high unmet medical needs.
- Building a sustainable innovation ecosystem that supports long-term value creation for patients, partners, and shareholders alike.
By combining Samsung’s proven operational excellence with Epis NexLab’s innovative research focus, the group aims to deliver a new paradigm in biotechnology—one that seamlessly integrates science, technology, and business strategy to accelerate the future of healthcare innovation.
About Epis NexLab
Founded in 2025 as a wholly owned subsidiary of Samsung Epis Holdings, Epis NexLab is dedicated to the development of next-generation biotechnology platforms. The company’s mission is to harness scalable, peptide-based, and conjugate technologies to discover and develop innovative therapeutic candidates targeting a broad range of diseases. Epis NexLab combines scientific innovation with strategic collaboration to accelerate the advancement of novel treatment modalities and drive the next chapter of global biotechnology leadership. For more information, visit: www.samsungepisholdings.com
Source Link: https://www.businesswire.com/
